checkAd
    Plus Therapeutics Registered (Old) Aktie
    0,2598
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 29.04.23 NYSE
    ISIN: US72941H4002 · WKN: A2PPX6 · USA

    Neueste Nachrichten

    Plus Therapeutics Announces Private Placement Financing of up to $18 Million
    06.05.24 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense
    22.04.24 · globenewswire · Plus Therapeutics Registered (Old)
    Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team
    09.04.24 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
    27.03.24 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
    25.03.24 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases
    11.03.24 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
    05.03.24 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024
    27.02.24 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Updates Financial and Cash Guidance for 2024
    18.12.23 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe
    29.11.23 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
    20.11.23 · globenewswire · Plus Therapeutics Registered (Old)
    Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023
    15.11.23 · globenewswire · Plus Therapeutics Registered (Old)